Harpoon Therapeutics, Inc.

$HARP has had a volatile last few days and has bounced off and found resistance at its 200DMA twice during that time. Today the company released positive results from its HPN328 trial in small cell lung cancer. The stock opened higher but faded during the day, creating a bearish engulfing pattern. $7.50 seems to be the next resistance level as of now.

Share This Article

 

About the Author

Harpoon Therapeutics, Inc.

Joey Ramson